tetano
Editor, Senior Moderator
Intest Res
. 2022 Jan 5.
doi: 10.5217/ir.2021.00098. Online ahead of print.
SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID
Yoo Jin Lee[SUP] 1 [/SUP], Seong-Eun Kim[SUP] 2 [/SUP], Yong Eun Park[SUP] 3 [/SUP], Ji Young Chang[SUP] 4 [/SUP], Hyun Joo Song[SUP] 5 [/SUP], Duk Hwan Kim[SUP] 6 [/SUP], Young Joo Yang[SUP] 7 [/SUP], Byung Chang Kim[SUP] 8 [/SUP], Jae Gon Lee[SUP] 9 [/SUP], Hee Chan Yang[SUP] 10 [/SUP], Miyoung Choi[SUP] 11 [/SUP], Seung-Jae Myung[SUP] 12 [/SUP], Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases (KASID)
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy.
Keywords: COVID-19; COVID-19 vaccines; Inflammatory bowel disease; SARS-CoV-2.
. 2022 Jan 5.
doi: 10.5217/ir.2021.00098. Online ahead of print.
SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID
Yoo Jin Lee[SUP] 1 [/SUP], Seong-Eun Kim[SUP] 2 [/SUP], Yong Eun Park[SUP] 3 [/SUP], Ji Young Chang[SUP] 4 [/SUP], Hyun Joo Song[SUP] 5 [/SUP], Duk Hwan Kim[SUP] 6 [/SUP], Young Joo Yang[SUP] 7 [/SUP], Byung Chang Kim[SUP] 8 [/SUP], Jae Gon Lee[SUP] 9 [/SUP], Hee Chan Yang[SUP] 10 [/SUP], Miyoung Choi[SUP] 11 [/SUP], Seung-Jae Myung[SUP] 12 [/SUP], Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases (KASID)
Affiliations
- PMID: 34974674
- DOI: 10.5217/ir.2021.00098
Abstract
Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy.
Keywords: COVID-19; COVID-19 vaccines; Inflammatory bowel disease; SARS-CoV-2.